Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

rasburicase (Elitek)

rasburicase is an FDA-licensed reference biologic from Sanofi-Aventis U.S. LLC.

351(a) biologicBLA 103946 Sanofi-Aventis U.S. LLC
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2006

Reference product

Originator biologic
351(a)BLA 103946

Elitek rasburicase

Sanofi-Aventis U.S. LLC

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for rasburicase from the RCSB Protein Data Bank (PDB 9QW5).

3D molecular structure of rasburicase (PDB entry 9QW5)

Interactive biological assembly from PDB entry 9QW5. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference rasburicase product.

    21 yr ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    17 yr 5 mo ago

rasburicase: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for rasburicase.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.